Stem cell transplantation for myelofibrosis: a report from two Canadian centers.

摘要: We describe the course of 25 patients with myelofibrosis (MF) due to agnogenic myeloid metaplasia (n=19) or essential thrombocytosis (n=6) who underwent allogeneic stem cell transplantation (SCT) at one two Canadian centers. The median age was 48.7 (IQR 45.9–50.4) years and carried out a 10.7 5.67–26.5) months after diagnosis. Granulocyte engraftment (absolute neutrophil count >0.5 × 109/l) occurred 20 days for splenectomized patients, compared 27.5 nonsplenectomized individuals (P=0.03). Increased risk grade II–IV acute graft-versus-host disease (P=0.04) noted in transplanted splenectomy. Patients MF received 0.264±0.189 U packed red blood cells per day over first 180 transplantation, remained dependent on transfusions 123 48–205) days. Complete remission documented 33% evaluable patients. 1 year cumulative nonrelapse mortality 48.3%. Median survival this group 393 109–1014+) days, projected 2-year overall 41%. conclude that SCT offers reasonable chance prolonged advanced MF, but occurs cost considerable toxicity mortality.